The US FDA has approved two more biosimilars in the form of Meitheal’s Garzulys (insulin aspart-fsan) rival to Novolog and the Fresenius Kabi and Dr Reddy’s partnered version of Rituxan (rituximab).
The US FDA has approved two more biosimilars in the form of Meitheal’s Garzulys (insulin aspart-fsan) rival to Novolog and the Fresenius Kabi and Dr Reddy’s partnered version of Rituxan (rituximab).